Vaccines for human papillomavirus (HPV) have been available in the United States since 2006.
Early studies have shown a high rate of effectiveness of these vaccines, however it is not
known how long this protection will last. The IMAP study will look at various parts of the
immune system and potential markers for long lived immune responses to this vaccine.
Details
Lead Sponsor:
Emory University
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)